Fox Run Management L.L.C. Buys 3,491 Shares of Natera, Inc. $NTRA

Fox Run Management L.L.C. boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 42.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,713 shares of the medical research company’s stock after acquiring an additional 3,491 shares during the quarter. Fox Run Management L.L.C.’s holdings in Natera were worth $1,885,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. MAI Capital Management raised its stake in shares of Natera by 3.7% in the 3rd quarter. MAI Capital Management now owns 2,133 shares of the medical research company’s stock valued at $343,000 after purchasing an additional 77 shares during the period. Abbot Financial Management Inc. grew its holdings in shares of Natera by 2.0% during the third quarter. Abbot Financial Management Inc. now owns 5,298 shares of the medical research company’s stock worth $853,000 after buying an additional 103 shares in the last quarter. Waddell & Associates LLC grew its holdings in shares of Natera by 35.7% during the third quarter. Waddell & Associates LLC now owns 2,023 shares of the medical research company’s stock worth $326,000 after buying an additional 532 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of Natera by 9.9% during the third quarter. TD Asset Management Inc now owns 129,606 shares of the medical research company’s stock worth $20,863,000 after buying an additional 11,658 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Natera by 7.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,089 shares of the medical research company’s stock valued at $336,000 after buying an additional 148 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Natera news, CFO Michael Burkes Brophy sold 37,175 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the sale, the chief financial officer owned 64,123 shares in the company, valued at $15,552,392.42. This represents a 36.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 23,205 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider directly owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 368,119 shares of company stock valued at $85,956,782. 5.63% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Stephens raised their price target on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. BTIG Research raised their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Morgan Stanley boosted their price target on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. UBS Group increased their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, JPMorgan Chase & Co. lifted their target price on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $249.20.

Natera Price Performance

Natera stock opened at $209.53 on Wednesday. The company’s 50-day moving average is $227.44 and its 200-day moving average is $203.04. The firm has a market capitalization of $28.98 billion, a PE ratio of -91.50 and a beta of 1.64. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.